1621-P: Period Prevalence of Chronic Kidney Disease and Obesity in Adults with Type 1 Diabetes

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 1621-P
Author(s):  
AMELIA WALLACE ◽  
ALEX R. CHANG ◽  
MORGAN GRAMS ◽  
ELIZABETH SELVIN
Diabetes ◽  
2021 ◽  
Vol 70 (Supplement 1) ◽  
pp. 455-P
Author(s):  
EMILY YE ◽  
JULIA STEVENSON ◽  
JACQUELINE TAIT ◽  
REBECCA GOWEN ◽  
SARA SUHL ◽  
...  

2018 ◽  
Vol 6 (1) ◽  
pp. e000521 ◽  
Author(s):  
Hiroki Yokoyama ◽  
Shin-ichi Araki ◽  
Koichi Kawai ◽  
Katsuya Yamazaki ◽  
Osamu Tomonaga ◽  
...  

ObjectiveWe examined changes in prevalence of diabetic microvascular/macrovascular complications and diabetes care indicators for adults in Japan with type 2 and type 1 diabetes over one decade.Research design and methodsTwo independent cohorts were recruited with the same inclusion criteria in 2004 (cohort 1: 3319 with type 2 and 286 with type 1 diabetes) and in 2014 (cohort 2: 3932 with type 2 and 308 with type 1 diabetes). Prevalence of complications and care indicators including achieving treatment targets for glycemia, blood pressure, lipid control, body mass index (BMI), and smoking were compared. In addition, patients in cohort 1 were re-examined in 2014 and their data were compared with the baseline data of each cohort.ResultsIn type 2 diabetes, the prevalence of nephropathy, retinopathy, neuropathy, chronic kidney disease, current smoking and stroke significantly decreased, with improvements in achieving treatment target rates in cohort 2 two as compared with cohort 1. In type 1 diabetes, the prevalence of nephropathy, retinopathy, chronic kidney disease, and hemoglobin A1Cvalues significantly decreased. Decreases in prevalence of microvascular complications in type 2 diabetes were similarly found in each age-matched and sex-matched group, whereas younger patients exhibited marked increase in BMI and lower treatment target achieving rates compared with elderly patients. Regarding normoalbuminuric renal impairment, only a slight increase in the prevalence was observed both in type 2 and type 1 diabetes. In cohort 1, re-examined in 2014, care indicators were significantly improved from 2004, while complications increased with getting 10 years older.ConclusionsWe observed declining trends of diabetic microvascular complications with improvement in diabetes care indicators in type 2 and type 1 diabetes. Younger patients with type 2 diabetes exhibited marked increase in BMI and lower rates of achieving treatment targets compared with elderly patients, which remains a concern.


2012 ◽  
Vol 08 (01) ◽  
pp. 40 ◽  
Author(s):  
George Jerums ◽  
Elif Ekinci ◽  
Sianna Panagiotopoulos ◽  
Richard J MacIsaac ◽  
◽  
...  

In the early 1980s, studies in type 1 diabetes suggested that glomerular filtration rate (GFR) loss begins with the onset of macroalbuminuria. However, recent evidence indicates that up to one-quarter of subjects with diabetes reach a GFR of less than 60 ml/min/1.73 m2(chronic kidney disease [CKD] stage 3) before developing micro- or macroalbuminuria. Furthermore, the prospective loss of GFR can be detected in early diabetic nephropathy (DN) well before CKD stage 3. Early GFR loss usually reflects DN in type 1 diabetes but, in older patients with type 2 diabetes, the assessment of early GFR loss needs to take into account the effects of aging. The assessment of GFR is now feasible at clinical level, using formulas based on serum creatinine, age, gender, and ethnicity. Overall, the estimation of early GFR loss is more accurate with the Chronic Kidney Disease Epidemiology (CKD–EPI) formula than with the Modification of Diet in Renal Disease (MDRD) study formula, but there is some evidence that the CKD-EPI formula does not exhibit better performance than the MDRD formula for estimating GFR in diabetes. Both formulas underestimate GFR in the hyperfiltration range. Formulas based on the reciprocal of cystatin C can also be used to estimate GFR, but their cost and lack of assay standardization have delayed their use at clinical level. In summary, early GFR loss is an important marker of DN as well as a potentially reversible target for interventions in DN.


2020 ◽  
Vol 12 (1) ◽  
Author(s):  
Marcela Haas Pizarro ◽  
Deborah Conte Santos ◽  
Laura Gomes Nunes Melo ◽  
Bianca Senger Vasconcelos Barros ◽  
Luiza Harcar Muniz ◽  
...  

Author(s):  
Rakhimova G.N. ◽  
◽  
Sadikova A.S. ◽  

The study aimed to assess the functional state of the kidneys and to study the relationship of I/D polymorphism of the ACE gene with the stage of chronic kidney disease in children and adolescents of the Uzbek population with type 1 diabetes according to the new recommendations of K/DOQI (2012). We examined 120 children and adolescents with type 1 diabetes. Clinical, biochemical and genetic studies have been carried out. The study revealed that children with diabetes in the stage of compensation (НbА1с ≤7.5%) have CKD stages II (28.6%) and III (4.8%). The use of the new classification K/DOQI (2012) reveals a decrease in kidney function at earlier stages, in 61.9% of children and adolescents with type 1 diabetes, even at the NAU stage, a GFR of 80.6 ± 7.5 ml/min/1.73m2, which corresponds to stage II of CKD and 16.7% have a GFR of 45.1 ± 9.5 ml/min/1.73m2, which corresponds to stage III of CKD. Also, 28.6% of children and adolescents at the MAU stage have CKD II, 75.0% of CKD stage III, respectively. ACE I/D polymorphism is a molecular genetic marker of susceptibility to the development of CKD type 1 diabetes in children and adolescents.


Sign in / Sign up

Export Citation Format

Share Document